title: Vemurafenib and cutaneous adverse events--report of five cases.
abstract: Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.
authors: AC Camargo Cancer Center, SP, BR.
authors: Giselle de Barros
authors: Gde B
authors: Silva
authors: AC Camargo Cancer Center, SP, BR.
authors: Adriana Pessoa
authors: AP
authors: Mendes
authors: AC Camargo Cancer Center, SP, BR.
authors: Mariana Petaccia
authors: MP
authors: de Macedo
authors: AC Camargo Cancer Center, SP, BR.
authors: Clóvis Antônio Lopes
authors: CA
authors: Pinto
authors: AC Camargo Cancer Center, SP, BR.
authors: Ivana Lameiras
authors: IL
authors: Gibbons
authors: AC Camargo Cancer Center, SP, BR.
authors: João Pedreira
authors: JP
authors: Duprat Neto
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf